DUBLIN, Ireland--(BUSINESS WIRE)--Aug. 1, 2006--Elan Corporation, plc today announced its second quarter 2006 financial results. Commenting on Elan’s business, Kelly Martin, Elan’s president and chief executive officer, said, “The second quarter, once again, reflected our continued discipline and focus on delivering tangible business results. We recently received approval in the US and Europe to make Tysabri available to patients suffering from MS. We have been diligently working to have this effective treatment available to patients and their physicians. We believe that Tysabri will play a significant role as a treatment alternative for patients suffering from this chronic and debilitating disease. We also have made important advances in all areas of our business, recently demonstrated by our alliances with Abbott in nanotechnology and Archemix in autoimmune. We continue to actively evaluate and pursue both internal and external opportunities that will reinforce our strategic focus, strengthen our capabilities and generate value as we move the enterprise forward.”
